Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- One-product, Two-brand Marketing Comes under Fire at CSIMC; Japanese Like Competition between Partners
October 1, 2012
- Nihon Chouzai Expects to Reach Agreement on Price Negotiations by End of September Despite Differences in Desired Prices
September 28, 2012
- Dilution-Free Formulation Approved for Zometa: Novartis
September 28, 2012
- GSK Ties Up with Tokyo University Venture for New Drug Candidate Exploration
September 28, 2012
- Eisai, Santen Conclude Option Agreement in Ophthalmologic Field
September 27, 2012
- Over 50,000 Patients Treated with Eli Lilly’s Forteo in 2 Years since Launch
September 27, 2012
- Kyowa Kirin Takes Full Control of South Korean Subsidiary
September 27, 2012
- GSK Files NDA for ICS/LABA Combination Drug for Asthma, COPD in Japan
September 27, 2012
- Santen to Establish New Sales and Marketing Subsidiary in China
September 27, 2012
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
- Janssen Pharmaceutical Files for Once-Monthly Schizophrenia Treatment in Japan
September 26, 2012
- Kyowa Pharmaceutical Voluntarily Recalls Allopurinol Tablets 100 mg
September 25, 2012
- Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
- Equa Tops Both GP, HP Markets in August: RepTrack Survey
September 24, 2012
- Most Top Drugstore Chains Plan to Continue Dispensing Point Services After October
September 24, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…